Baxter International today spun off its Baxter BioScience global biopharmaceutical business into Baxalta, saying the new company will focus on developing new treatments for people with orphan diseases and underserved conditions.

Baxalta said it will build on its strengths in hematology and immunology, while seeking to expand its oncology portfolio for patients with limited treatment options. The new company also aims to build on its base of $6 billion in annual revenues, saying it plans to generate an additional $2.5 billion in sales by 2020 through launches of 20 new products as well as new indications for existing products.

As part of Baxter, the company received seven approvals for new products over the past two years. Baxalta begins life with four products under regulatory review across its three areas of therapeutic focus:

  • Hematology: Baxalta will add to its roster of existing products, including Advate [Antihemophilic Factor (Recombinant)] and Feiba [Anti-Inhibitor Coagulant Complex (Human)] with new offerings that include BAX 855, an extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A to be marketed in the U.S. as Adynovate [Antihemophilic Factor (Recombinant), Pegylated].


  • Immunology: The company hopes to expand its immune globulin portfolio with a successful launch of Hyqvia [Immune Globulin Infusion 10% (human) with Recombinant Human Hyaluronidase] for adults with primary immunodeficiency.


  • Oncology: Baxalta has filed for approvals with the FDA and European regulators to market MM-398 (irinotecan liposome injection), co-developed with Merrimack Pharmaceuticals for metastatic pancreatic cancer. In March, Baxter and partner CTI BioPharma announced positive Phase III PERSIST-1 trial results for the myelofibrosis treatment pacritinib.

Also on the cancer front, Baxalta plans to add the Oncaspar® (pegaspargase) product portfolio for acute lymphoblastic leukemia (ALL), which Baxter said in May it was buying from Sigma-Tau Finanziaria for $900 million. The deal is expected to close in the second half of 2015.

In hematology, Baxalta will advance a Phase I/II open-label clinical trial assessing the safety and optimal dosing level of a factor IX (FIX) gene therapy treatment for hemophilia B. The gene therapy “has the potential to redefine the treatment of hemophilia,” the company says, by providing a mechanism for the patient's own liver to begin producing FIX over an extended period.

Baxalta said it will capitalize on recently acquired technology platforms in immunology and hematology. Baxter in March bought SuppreMol and its portfolio of autoimmune and allergic disease candidates for $225 million, and last year acquired AesRx, whose lead product is the sickle cell disease candidate Aes-103, for an undisclosed price.

The new company also promises to maintain a significant R&D operation, which according to the company is now overseeing more than 40 programs in development, 13 of them in late stages.

Baxalta employs 16,000 people worldwide, and is headquartered in Deerfield, IL—the headquarters city of its predecessor Baxter—with a Global Innovation and R&D Center set to formally open later this year in Cambridge, MA. A company spokesman told the Boston Business Journal last week that Baxalta is “on track” to have about 400 employees—mostly scientists and business development specialists—based in Cambridge by next year.

Baxalta begins trading shares today on the New York Stock Exchange under the symbol BXLT.

Previous articleSynthetic Stem Cells Might Eventually Lead to Artificial Organs
Next articleHigh Cholesterol Good for Hantavirus